News about Global Pharma

Nuvation Bio Gets US FDA sNDA Approval for IBTROZI

Nuvation Bio has announced US FDA approval of sNDA for IBTROZI (taletrectinib), updating duration of response in TKI-naïve ROS1-positive NSCLC.

Global Pharma | 19/09/2026 | By News Bureau |  124

Gilead Accelerates Access to Once-Yearly HIV Drug

Gilead speeds global access for once-yearly HIV drug lenacapavir, signing 6 royalty-free licensing deals for supplying in 120 high-incidence countries.

Global Pharma | 18/09/2026 | By News Bureau

Viatris Gets Approval for WAKIX in Japan

Viatris has got approval for WAKIX (Pitolisant), a first-in-class treatment for narcolepsy and Excessive Daytime Sleepiness (ESD) from sleep apnea, in Japan.

Global Pharma | 18/09/2026 | By News Bureau

Japan Approves Leqembi Pen, a Subcutaneous Formulation

Japan has approved Leqembi Pen, a once-weekly subcutaneous (SC) formulation for early Alzheimer's, offering at-home dosing alongside the intravenous (IV) option.

Global Pharma | 17/09/2026 | By News Bureau |  130

US FDA Approves Telix's Brain Cancer Imaging Drug Pixclara

The US Food and Drug Administration (FDA) has approved Telix’s Pixclara, the first FET-PET imaging drug for glioma, helping differentiate recurrent or progressive brain cancer from treatment-related changes.

Global Pharma | 15/09/2026 | By News Bureau |  201

Sun Pharma Subsidiaries Reach Settlement in US Generic Drug Pricing Antitrust Litigation

Sun Pharma subsidiaries have reached a settlement with a plaintiff in a US generic drug pricing antitrust case for a confidential amount.

Global Pharma | 15/09/2026 | By News Bureau |  116

Accro Bioscience's AC-101 Enters NMPA Rare Disease Development Pilot Program

Accro Bioscience’s AC-101, a novel selective RIPK2 inhibitor, enters the NMPA CDE Caring Plan-Extension pilot program for rare disease drug development.

Global Pharma | 14/09/2026 | By News Bureau |  130

J&J's RYBREVANT Plus Chemotherapy Delivers Nearly 3-Year Survival in EGFR Exon 20 NSCLC

J&J’s RYBREVANT (amivantamab) plus chemotherapy delivers a median Overall Survival of 34.3 months in EGFR exon 20 insertion mutation-positive Non-Small Cell Lung Cancer (NSCLC).

Global Pharma | 14/09/2026 | By News Bureau |  113

WHO Prequalifies Multi-Dose Maternal RSV Vaccine Presentation

WHO has prequalified a multi-dose vial presentation of RSVpreF to support wider access to maternal RSV vaccination and help protect infants from severe respiratory illness.

Global Pharma | 11/09/2026 | By News Bureau |  105

Gilead Sciences Opens 182,000-Sq-Ft Research Centre at Foster City Headquarters

Gilead Sciences has opened a 182,000-square-foot research centre in Foster City, expanding its capabilities in oncology, inflammation and research data science.

Global Pharma | 10/09/2026 | By News Bureau |  111